Back to Journals » Therapeutics and Clinical Risk Management » Volume 16

Management Strategies of Patients with Neuromyelitis Optica Spectrum Disorder During the COVID-19 Pandemic Era

Authors Hamdy SM, Abdel-Naseer M, Shehata HS, Shalaby NM, Hassan A, Elmazny A, Shaker E, Nada MAF, Ahmed SM, Hegazy MI, Mourad HS, Abdelalim A, Magdy R, Othman AS, Mekkawy DA, Kishk NA

Received 12 May 2020

Accepted for publication 3 August 2020

Published 17 August 2020 Volume 2020:16 Pages 759—767

DOI https://doi.org/10.2147/TCRM.S261753

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Editor who approved publication: Professor Garry Walsh


Sherif M Hamdy, Maged Abdel-Naseer, Hatem S Shehata, Nevin M Shalaby, Amr Hassan, Alaa Elmazny, Ehab Shaker, Mona AF Nada, Sandra M Ahmed, Mohamed I Hegazy, Husam S Mourad, Ahmed Abdelalim, Rehab Magdy, Alshimaa S Othman, Doaa A Mekkawy, Nirmeen A Kishk

Neurology Department, Faculty of Medicine, Cairo University, Cairo, Egypt

Correspondence: Alaa Elmazny 66-Manial-Street, Cairo, Egypt
Tel +966536012237
Email alaa_elmazny@kasralainy.edu.eg

Abstract: The ongoing coronavirus (COVID-19) pandemic is a global health emergency of international concern and has affected management plans of many autoimmune disorders. Immunosuppressive and immunomodulatory therapies are pivotal in the management of neuromyelitis optica spectrum disorder (NMOSD), potentially placing patients at an increased risk of contracting infections such as COVID-19. The optimal management strategy of NMOSD during the COVID-19 era remains unclear. Here, however, we examined the evidence of NMOSD disease-modifying therapies (DMTs) use during the present period and highlighted different scenarios including treatment of relapses as well as initiation and maintenance of DMTs in order to optimize care of NMOSD patients in the COVID-19 era.

Keywords: neuromyelitis optica spectrum disorder, COVID-19, pandemic

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]